Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

ImmunityBio (IBRX) Accumulated Depreciation & Amortization (2016 - 2025)

ImmunityBio (IBRX) has disclosed Accumulated Depreciation & Amortization for 12 consecutive years, with $15.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 11.56% to $15.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.5 million, a 11.56% decrease, with the full-year FY2025 number at $15.5 million, down 11.56% from a year prior.
  • Accumulated Depreciation & Amortization was $15.5 million for Q4 2025 at ImmunityBio, up from $11.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $18.5 million in Q4 2023 to a low of $3.0 million in Q1 2021.
  • A 5-year average of $10.4 million and a median of $10.0 million in 2021 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: plummeted 85.73% in 2021, then skyrocketed 37.62% in 2022.
  • ImmunityBio's Accumulated Depreciation & Amortization stood at $14.2 million in 2021, then grew by 28.25% to $18.3 million in 2022, then increased by 1.38% to $18.5 million in 2023, then decreased by 5.18% to $17.6 million in 2024, then fell by 11.56% to $15.5 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Accumulated Depreciation & Amortization are $15.5 million (Q4 2025), $11.7 million (Q3 2025), and $7.7 million (Q2 2025).